SCHEMBL7148433

SCHEMBL7148433

COc1ccccc1NS(=O)(=O)CCCCSc1nc2cc3c(cc2s1)OCO3

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.46
RAB9A P51151 4/20 0.46
NPC1 O15118 3/20 0.46
MAPT P10636 8/20 0.44
ALDH1A1 P00352 5/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
LMNA P02545 5/20 0.41
HTT P42858 3/20 0.41
MAPK1 P28482 1/20 0.41
THRB P10828 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
HCRTR1 O43613 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
NPSR1 Q6W5P4 2/20 0.39
RXFP1 Q9HBX9 1/20 0.39
POLB P06746 1/20 0.39
HPGD P15428 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7146193 0.97 KDM4E (0.47) KDM4ERAB9ANPC1MAPTALDH1A1
SCHEMBL7149158 0.94 KDM4E (0.48) KDM4ERAB9ANPC1MAPTALDH1A1
SCHEMBL7151259 0.89 ALDH1A1 (0.46) RAB9ANPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL7153029 0.86 ALDH1A1 (0.46) RAB9ANPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL7147149 0.85 MAPT (0.43) KDM4ERAB9ANPC1MAPTALDH1A1
SCHEMBL7149211 0.84 ALDH1A1 (0.53) KDM4ERAB9ANPC1MAPTALDH1A1
SCHEMBL7149163 0.84 MAPT (0.46) KDM4ERAB9ANPC1MAPTALDH1A1
SCHEMBL7146609 0.84 MAPT (0.42) MAPTALDH1A1SMN1; SMN2LMNAHTT
SCHEMBL7149243 0.84 MAPT (0.51) RAB9ANPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL7153034 0.83 MAPT (0.44) KDM4ERAB9ANPC1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642263-B2 Antitumor agents, sulfided benzothiazole derivative containing sulfonamide ICONIX PHARMACEUTICALS INC. 2003-11-04 US disclosed
US-20030176474-A1 Modulators of Rho C activity ICONIX BIOSCIENCES, INC. 2003-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176474-A1 Modulators of Rho C activity RHOC, ARHGDIA, ROCK1 KDM4E 3463/4885RAB9A 84/4885NPC1 1040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.